Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...
The last time I wrote an article on Structure Therapeutics Inc. (GPCR) it was in a Seeking Alpha article entitled "Structure Therapeutics: Potential To Have Best-In-class GLP-1 Agonist For Obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results